Neusoft Medical Secures NMPA Approval for AI Imaging Platform NeuSpace and NeuSpace.CT

Neusoft Medical announced on September 20 that its self-developed NeuSpace multimodal intelligent imaging post-processing platform has received NMPA market approval, along with NeuSpace.CT, an AI software product focused on CT imaging. As the core carrier of the company's comprehensive AI strategy, NeuSpace embeds AI into clinical imaging workflows, marking a shift toward AI-native platform services for medical imaging post-processing.

The platform combines AI capabilities with imaging processing workflows, offering intelligent image output, second-level image analysis, quality control and risk alerts, and full-cycle patient services. It supports hospital deployment, hospital-wide access, multi-terminal and cross-platform access, and customizable workflows, allowing multiple departments to use intelligent imaging services in daily diagnosis and treatment.

NeuSpace.CT, the first product on the platform, is equipped with a multimodal large-model engine for automatic CT image recognition and analysis. Its application suite covers 44 diseases across the body, provides 78 applications, and supports six imaging modalities, forming seven core solutions for stroke, auditory system imaging, musculoskeletal quantification, chronic respiratory disease, cardiac panoramic imaging, systemic vasculature, and Aurora spectroscopy.

To handle the rapidly growing volume of imaging data, NeuSpace.CT integrates a "Lingyu" bio-cognitive compression engine that can reduce data storage requirements from 200GB to 20GB, cutting storage space by 90% and improving image retrieval and transfer efficiency by nearly 100 times.

In research, Neusoft Medical is working with multiple hospitals and industry partners to build a "total vascular digital twin" exploration platform based on photon-counting CT and NeuSpace, using photon imaging to train a world model and create physical AI for medical devices.